Product Information
MOMETASONE FUROATE 0.1% OINT is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.2922 per GM under NDC 45802011937. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Mar 18, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802011937
Classification
Generic
Dosage Form
OINTMENT
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
MOMETASONE FUROATEApproval Type
Generic (ANDA)
FDA Application
ANDA076067FDA Approved
3/18/2002
TE Code
AB
On Market Since
7/18/2008
Pharmacological Classes
Price Statistics
The NADAC for MOMETASONE FUROATE 0.1% OINT has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 29.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2922 per GM |
|---|---|
| All-time high | $0.6681 (Feb 12, 2014) |
| All-time low | $0.2383 (Jan 22, 2020) |
| 52-week high | $0.3226 |
| 52-week low | $0.2922 |
| Median price | $0.3318 |
| Average price | $0.3604 |
| Largest weekly change | +49.7% (Jan 22, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 29% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mometasone Furoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MOMETASONE FUROATE 0.1% OINT?
The current National Average Drug Acquisition Cost (NADAC) for MOMETASONE FUROATE 0.1% OINT, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.2922 per GM (NDC 45802011937), effective Sep 30, 2026.
How has the price of MOMETASONE FUROATE 0.1% OINT changed over time?
Over the history we have for it, the NADAC for MOMETASONE FUROATE 0.1% OINT has declined 29.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MOMETASONE FUROATE 0.1% OINT?
Since Nov 28, 2013, the NADAC for MOMETASONE FUROATE 0.1% OINT has ranged from a low of $0.2383 (Jan 22, 2020) to a high of $0.6681 (Feb 12, 2014), with a median of $0.3318 per GM.
Are there cheaper alternatives to MOMETASONE FUROATE 0.1% OINT?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MOMETASONE FUROATE 0.1% OINT, is $0.2077 per GM — about 29% below MOMETASONE FUROATE 0.1% OINT.
Who manufactures MOMETASONE FUROATE 0.1% OINT?
MOMETASONE FUROATE 0.1% OINT (NDC 45802011937) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.